Journal
JOURNAL OF HEPATOLOGY
Volume 78, Issue 6, Pages 1199-1215Publisher
ELSEVIER
DOI: 10.1016/j.jhep.2023.01.030
Keywords
alloimmune disease; immunosuppression; T cell-mediated rejection; antibody-mediated rejection; immune checkpoint inhibitors
Categories
Ask authors/readers for more resources
The outcomes of liver transplantation have improved over the years, but long-term survival rates are still lower than the general population. The liver has unique immunological functions and can modulate the recipient's immune system to promote tolerance. Immunosuppressive drugs should be individualized to control alloreactivity while minimizing toxicities.
Outcomes after liver transplantation have continuously improved over the past decades, but long-term survival rates are still lower than in the general population. The liver has distinct immunological functions linked to its unique anatomical configuration and to its harbouring of a large number of cells with fundamental immunological roles. The transplanted liver can modulate the immu-nological system of the recipient to promote tolerance, thus offering the potential for less aggressive immunosuppression. The selection and adjustment of immunosuppressive drugs should be individualised to optimally control alloreactivity while mitigating toxicities. Routine laboratory tests are not accurate enough to make a confident diagnosis of allograft rejection. Although several promising biomarkers are being investigated, none of them is sufficiently validated for routine use; hence, liver biopsy remains necessary to guide clinical decisions. Recently, there has been an exponential increase in the use of immune checkpoint inhibitors due to the unquestionable oncological benefits they provide for many patients with advanced-stage tumours. It is expected that their use will also increase in liver transplant recipients and that this might affect the incidence of allograft rejection. Currently, the evidence regarding the efficacy and safety of immune checkpoint inhibitors in liver transplant recipients is limited and cases of severe allograft rejection have been reported. In this review, we discuss the clinical relevance of alloimmune disease, the role of minimisation/withdrawal of immunosuppression, and provide practical guidance for using checkpoint inhibitors in liver trans-plant recipients. (c) 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available